Zosano Pharma (ZSANQ) 10-Q2017 Q1 Quarterly report

Filed: 9 May 17, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: adhesive, agent, anniversary, array, attached, attributable, avoiding, bed, capillary, clarified, coated, commencement, comply, composed, convenient, core, cover, criteria, deconsolidate, Deferral, Derecognition, derecognize, differentiate, director, dissolution, easy, entitled, essentially, evergreen, exceed, FDIC, Federal, feedback, fourth, fully, GI, highly, hold, largely, lessor, midpoint, modified, nomination, Nonfinancial, nonprofit, opted, owner, Pacific, past, patented, penetrate, plant, platform, principle, promised, proposal, provision, resent, restricted, Secretary, section, settled, simplification, simplified, stockholder, subheading, Subtopic, technical, therapeutic, thereunder, titanium, Topic, tract, trading, uncertainty, underwritten, uniform, vote, Wednesday

Removed: acceleration, accounted, achievement, agency, ALZA, amortized, arm, Asahi, ASC, assigned, assure, beneficially, ceased, CEO, comprehensive, comprised, comprising, conclusion, concurrent, concurrently, confirming, consummated, continued, converted, dated, deferred, Delaware, diary, discontinue, Disposal, divided, dividend, Draft, effected, effectively, effort, Eli, elimination, enable, enhance, enroll, entity, entry, expand, exposure, extend, failure, fairly, feasibility, fee, feet, field, fixed, free, government, Group, hypothetical, increased, IND, individual, infrastructure, initially, intention, issuing, Johnson, joint, Kasei, key, landlord, largest, leased, licensed, Lilly, LLC, longer, low, Macroflux, merged, met, mg, Nordisk, notified, Novo, originally, outplacement, overallotment, partial, permanent, placement, portion, position, positive, postemployment, prepaying, prioritize, profile, realized, recapitalization, recapitalize, recapture, reclassification, reclassified, recovery, reduced, remaining, renegotiated, repayment, reserved, restructuring, resulted, revaluation, reverted, rolled, select, selection, senior, separate, servicing, source, spun, square, state, submission, surviving, suspend, suspended, temporary, treated, unpaid, unrealized, unvested, upfront, upper, USA, venture, worth, yield

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

ZSANQ similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, John Walker, the Interim Chief Executive Officer of Zosano Pharma Corporation (the “Company”), and Georgia Erbez, the Chief Financial Officer and Chief Business Officer of the Company, hereby certify that, to their knowledge:

1. The Quarterly Report on Form 10-Q for the period ended March 31, 2017 of the Company (the “Report”) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: May 9, 2017	By:	/s/ John Walker
		John Walker
		Interim Chief Executive Officer
		(Principal Executive Officer)

Date: May 9, 2017	By:	/s/ Georgia Erbez
		Georgia Erbez
		Chief Financial Officer and Chief Business Officer
		(Principal Financial Officer)